🔗 Share this article

While the US proceeds with unprecedented revisions to its vaccine guidelines, one figure appears in a surprising turn: Tracy Beth Høeg, a Danish American sports physician and public health researcher who rose to prominence by expressing skepticism about COVID-19 shots during the global health crisis and has concentrated on potential deaths following COVID-19 immunization in her brief position at the FDA.

Proposed Overhauls to Pediatric Immunization Program

Health officials had intended to unveil sweeping changes to the childhood vaccination calendar in December, aligning the US with the Danish immunization schedule, it is understood – a substantial departure that would place the US out of alignment with many the global community with no evidence for benefit. The announcement has been delayed until the new year.

Instead of the director of the vaccine center, Dr. Høeg is scheduled to speak at the event. She was newly appointed temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to lead the center this year.

A New Direction at the FDA

Høeg's temporary position may indicate a tighter collaboration between the pharmaceutical and biologics divisions as Dr. Høeg and Dr. Prasad solidify control at the agency – and it signals a greater focus upon reevaluating already-approved immunizations at the FDA.

Dr. Høeg has frequently advocated for discontinuing some childhood shot schedules in the US to become more like Denmark's approach, a nation with comprehensive healthcare and a population roughly the size of Wisconsin’s.

In her initial comments, she has kept her attention on immunizations – traditionally the domain of Dr. Prasad, head of the FDA’s vaccine center – instead of drug regulation.

Concerns Over Qualifications

Høeg has no obvious experience in drug development, approval processes or administrative roles, which has been standard for past directors of the Center for Biologics Evaluation and Research. She has served at the FDA as a top consultant to the FDA chief and the vaccine center since earlier this year.

“It seems she lacks to have the necessary background” for overseeing the CDER, said Jonathan Howard. “She has not conducted a scientific study. She is not versed in managing a sizeable institution. She lacks background in industry regulation.”

Previous commissioners of CBER would “grasp regulatory frameworks and the science of pharmaceutical innovation”, said Janet Woodcock. “Objectively, she has not acquired the kind of background that prior appointees who ran CBER have had.”

This division has an enormous range of responsibilities at the FDA, Woodcock pointed out.

“The public just pays attention on the innovative therapies, but the generic drug division clears numerous generic drugs. There’s a biologic copycat branch, OTC medication office and other areas, and all of those must be looked after,” she explained. “The thing you neglect, that is the part that I always told people is going to come back to haunt you.”

There is also, a substantial leadership component to the role, which oversees over 5,000 employees. “It is a massive administrative position, if you perform it correctly,” Woodcock concluded.

Agency Reaction and Disputed Policies

When asked about concerns about Høeg’s fitness for the role and whether this appointment indicates increased cooperation among FDA leaders on immunizations, a press secretary responded that the “concerns are based on incorrect assumptions”.

“Her resume is consistent with the duties of her position,” the representative said, noting the time Dr. Høeg spent guiding the FDA commissioner on “medication safety and regulatory science, including computational safety modeling and vaccine surveillance”.

As acting director, Høeg inherits the agency head's new fast-track approval initiative, a controversial one-day medication authorization process that reportedly troubled her preceding directors. “How are these therapies being selected for this voucher program? Who makes the choices?” Dr. Howard questioned. “There’s a lot of confidentiality going on at the regulatory body right now.”

Overall, he remarked, “the agency seems to be moving towards less stringent rules of most medications, except for shots.”

Public Track Record on Vaccines

Concerning immunizations, Høeg has a more documented, if problematic, past, some experts said. She authored a research paper using unverified public submissions to assess the incidence of heart inflammation following Covid immunization. She advised the Florida top health official Dr. Joseph Ladapo, who was said to have altered data to suggest Covid vaccines are pose a greater threat than they are.

Among her “desired changes” for the new government encompassed changing rules for new vaccines and halting “non-essential” immunizations, she remarked after the election on a online show. At the agency, Høeg has allegedly suggested preventing adolescent males from receiving Covid vaccinations.

“She is an all-around true believer who starts off with her beliefs and tailors the evidence to fit the science in a very deceptive, untruthful fashion,” Howard stated.

Consolidating Power and a “Push for Payback”

Høeg became part of other skeptics, {like|